Risperdal

J&J Earnings Hurt by Children's Medicine Recalls

Tylenol and Band-Aid maker Johnson & Johnson announced on Tuesday that its sales declined 0.7% to $15 billion in the third quarter, compared to the same quarter last year, as domestic sales were "significantly impacted" by recent successive recalls. Domestic sales declined 2.5%.

Johnson & Johnson Fights Charges of Recalls and Kickbacks

Johnson & Johnson shares are rebounding as the drugmaker tries to recover from a rough week, when the Justice Department charged it with paying kickbacks to a pharmacy company to boost sales of its drugs to nursing-home patients, and the Food and Drug Administration accused it of being too slow with its product recall during a Tylenol scare.